Massachusetts General Hospital Cancer Center to Use the Helicos™ Genetic Analysis System
This single-molecule sequencing technology overcomes disadvantages of DNA amplification.
Massachusetts General Hospital (MGH) Cancer Center will be using the Helicos™ Genetic Analysis System. This system is the only commercially available, single-molecule sequencing technology, according to Helicos BioSciences.
The Helicos Analysis System will be used in the laboratory of Daniel Haber, M.D., Ph.D. Genetic analysis with Helicos’ technology reportedly eliminates the biases, complexity, and errors introduced by DNA amplification, requires minute amounts of starting material, and provides a direct and an accurate view of biological samples.
“We are very excited to be working with the distinguished group led by Dr. Haber,” states Patrice Milos, CSO of Helicos. “We expect great synergies for cancer research and diagnostics with the combination of two powerful technologies: MGH’s revolutionary circulating tumor cell microchip and Helicos’ single-molecule genetic-analysis system.”